Dr Reddy’s registers immunotherapy for rare head and neck cancer in South Africa
Hyderabad, Aug 3 (TNT): Dr. Reddy’s Laboratories on Monday announced the registration of a PD-1 immunotherapy in South Africa for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare and aggressive form of head and neck cancer, marking a significant step in expanding access to advanced oncology treatment in the country.
The registration addresses a critical unmet need in oncology care, as treatment options for recurrent or metastatic nasopharyngeal carcinoma have remained limited despite advances in cancer therapy, Hyderabad based pharma giant said in a release.
The newly registered therapy is an immunotherapy that works by enabling the body’s immune system to recognise and fight cancer cells, unlike conventional chemotherapy, which directly targets rapidly dividing cells.
Commenting on the development, Dr. Rashem Mothilal, General Manager, Dr. Reddy’s Laboratories South Africa, said the registration represents an important step towards improving access to innovative treatment options for patients suffering from recurrent or metastatic nasopharyngeal carcinoma in South Africa.
The company noted that nasopharyngeal carcinoma is among the rarest forms of head and neck cancer and is often diagnosed at an advanced stage because its early symptoms—including persistent nasal congestion, hearing loss, recurrent ear infections and swollen lymph nodes—closely resemble common medical conditions.
Dr. Reddy’s said the registration forms part of its broader strategy to expand access to innovative cancer therapies and improve outcomes for patients with rare and underserved diseases.
The company also stressed the importance of early diagnosis and urged people experiencing persistent or unexplained symptoms to seek timely medical advice.
TNT TS
